Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') today announced its revenues and cash position for the first nine months of 2022.

Innate's strong financial position, innovative science and strategic collaborations enable us to progress a focused pipeline of antibodies, including several potentially first-in-class clinical and preclinical candidates, in cancers with high unmet medical need.' said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. 'We are pleased to see that lacutamab continues to show clinical activity in mycosis fungoides. We look forward to sharing data from the Phase 2 TELLOMAK trial for lacutamab in Sezary syndrome at ASH, as well as shining the spotlight on our proprietary ANKET platform, which demonstrates an important role in activating an anti-tumor response. Our third strategic pillar continues to advance, as part of our collaboration with AstraZeneca the PACIFIC-9 Phase 3 study of monalizumab in the early non-small cell lung cancer setting.'

Corporate Update

On May 03, Innate announced the commencement of an At-The-Market (ATM) program, pursuant to which it may, from time to time, offer and sell to eligible investors a total gross amount of up to $75 million American Depositary Shares ('ADS'). Each ADS representing one ordinary share of Innate. As of September 30, 2022, the balance available under our May 2022 sales agreement remains at $75 million.

Financial Results

Cash, cash equivalents and financial assets of the Company amounted to EUR151.4 million as of September 30, 2022. At the same date, financial liabilities amounted to EUR43.1 million.

Revenues for the first nine months of 2022 amounted to EUR44.3 million (EUR10.3 million for the same period in 2021). For the nine-month period, ended September 30, 2022, revenue from collaboration and licensing agreements mainly results from the spreading of the payments received under our agreements with AstraZeneca and Sanofi.

Contact:

Tel: +33 (0)4 30 30 30 30

(C) 2022 Electronic News Publishing, source ENP Newswire